Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05027633 · ClinicalTrials.gov registry record · Phase 2

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

A Phase 2 study of Squamous Cell Carcinoma and the Nasal Cavity, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
35
Enrollment target
1
Study location

NCT05027633 is a Phase 2 study of Squamous Cell Carcinoma and the Nasal Cavity that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 35 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05027633, a Phase 2 study of Squamous Cell Carcinoma and the Nasal Cavity, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell carcinoma of the nasal cavity/paranasal sinuses (PNS SCC).

Conditions Studied

Squamous Cell Carcinoma the Nasal Cavity Paranasal Sinuses

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Docetaxel
  • DRUG Cisplatin

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2021-11-02
Est. Completion 2028-03-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05027633

The ClinicalTrials.gov registry entry for NCT05027633 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (66% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT05027633 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05027633 about?

NCT05027633 is a clinical study titled "Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)". This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell carcinoma of the nasal cavity/paranasal sinuses (PNS SCC).

What is the current status of trial NCT05027633?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2021-11-02. Estimated completion is 2028-03-30.

What conditions does trial NCT05027633 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses.

What interventions are being tested in trial NCT05027633?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Cisplatin (DRUG).

Who is sponsoring clinical trial NCT05027633?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05027633 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Cell Carcinoma

All registered trials for this condition

the Nasal Cavity

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.